This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
For artificial intelligence to truly transform care, the healthcare industry must address certain challenges. Jens Eldrup-Jorgensen, MD, a veteran vascular surgeon and member of the Society for Vascular Surgery, explains in a guest editorial.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
After being bought by private equity firms, hospitals tend to see significant increases in inpatient falls and infections, according to new research published in JAMA.
In 2018, almost a quarter of surveyed Americans expected healthcare to be among the earliest and hardest hit of all employment sectors. However, in 2023, McKinsey & Co. projected overall demand for healthcare workers to grow by 30% by 2030.
Private equity is becoming more and more influential in many healthcare specialties, including cardiology. This has prompted increased speculation about the impact such investments may have on patient outcomes.
Seeking to thwart transmission of communicable respiratory diseases among patients, visitors and staff, hospitals in a handful of states have reinstated masking mandates.
For AI to achieve sweeping adoption across U.S. medicine, physicians will need to be assured they won’t be held liable should clinical algorithms make mistakes.
The Women’s Choice Award is out with its 2024 lists of best hospitals for women across 19 categories, from bariatrics and cancer care to stroke care and women’s services.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
